ArticleVascular health and risk management2026
Drug-Coated Balloon Angioplasty for de Novo Subclavian Artery Stenosis: Mid-Term Outcomes and Independent Risk Factors for Restenosis.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endovascular intervention is the first-line treatment for subclavian artery stenosis, but high-quality evidence for drug-coated balloon (DCB) angioplasty specifically in de novo lesions remains limited. This study aimed to evaluate the safety and efficacy of DCB for de novo subclavian artery stenosis and to identify independent risk factors for restenosis. Methods: This single-center retrospective cohort study enrolled 53 consecutive patients with de novo subclavian artery stenosis (≥70% confirmed by quantitative coronary angiography, QCA) treated with a paclitaxel-coated balloon (3.0 μg/mm Results: Mean age was 62.7±8.5 years (62.3% male). Technical success rate was 100%, with mean residual stenosis of 11.5±4.9%. Median follow-up was 24 months (IQR 12-36 months, range 6-74 months). Primary patency rates at 12, 24, and 36 months were consistently 94.3% (95% CI 87.6-100%), with all 3 restenosis cases detected at the 12-month CTA follow-up; all were asymptomatic and no CD-TLR was performed. Overall MACCE incidence was 3.8%. Severe lesion calcification (Grade 3) was the only independent risk factor for restenosis on multivariate Cox regression (HR=7.89, 95% CI 1.45-42.96, P=0.017); however, given the small number of events (n=3), these results should be interpreted with caution. Conclusion: DCB angioplasty demonstrates favorable safety and mid-term patency for de novo subclavian artery stenosis in this single-center retrospective cohort. Severe calcification is associated with poorer patency outcomes, though this finding requires validation. These preliminary results suggest DCB as a potential endovascular option for non-severely calcified de novo subclavian lesions; however, the absence of a direct comparator group and the retrospective single-center design limit definitive efficacy conclusions, and prospective comparative studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.